PT -期刊文章AU -爱德华Faught盟宣李盟-崔Jiyoon盟Manoj Malhotra AU -拉塞尔·l·Knoth TI -住院病人住院治疗风险Perampanel治疗前后患者癫痫(p3.5 - 022) DP - 2019年4月09年TA -神经病学第六PG - p3.5 - 022 - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_supplement/p3.5 022. - 022.短4100 - h首页ttp://www.ez-admanager.com/content/92/15_supplement/p3.5 - -全所以Neurology2019 4月09年;92 AB -目的:评估住院病人住院治疗风险perampanel启动后癫痫患者。背景:Perampanel,非竞争性AMPA谷氨酸受体拮抗剂,被批准治疗部分性癫痫的儿童和成人癫痫患者4岁及以上,以及辅助治疗主要广义tonic-clonic发作癫痫患者12岁及以上。设计/方法:交响曲健康,具有全国代表性的医学和药学数据库,被用于这项研究。患者发现如果他们填补了perampanel处方2014年7月到2016年6月期间。索引日期的日期的第一个填充药物。患者选择如果他们4岁与任何部分性癫痫(POS)(焦),或12岁或以上程度,任何POS或任何主要广义tonic-clonic癫痫(gtc),并连续观察一段这个日期之前还是之后。感兴趣的结果变量是为期一年的所有原因和epilepsy-related perampanel启动后住院病人的住院治疗的相对风险。结果:1771例患者纳入本研究。平均年龄33岁,55%是女性。预先索引时期相比,post-perampanel时期与住院病人住院的风险显著降低。一年期全因住院病人住院治疗风险比为0.76 (p & lt; 0.05), with a risk of 36.2% during the pre-index compared to 29.5% in the one year follow-up. Similarly, the one-year epilepsy-related inpatient hospitalization risk ratio was 0.72 (p<0.05), with 30.8% during the pre-index period, compared to 23.9% during the follow-up period.Conclusions: In patients with epilepsy, treatment with perampanel, relative to the one-year period prior to perampanel initiation, was associated with a significant reduction in one-year all-cause and epilepsy-related inpatient hospitalization risk.Disclosure: Dr. Faught has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with As a KOL for Eisai inc. Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Choi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Inc. Dr. Malhotra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc. Dr. Knoth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Inc.